{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:11:55Z","timestamp":1793160715967,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41409-024-02427-8","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T14:02:08Z","timestamp":1728482528000},"page":"32-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Role of bridging RT in relapsed\/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-7991","authenticated-orcid":false,"given":"Stefania","family":"Bramanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-6896","authenticated-orcid":false,"given":"Daniele","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-0098","authenticated-orcid":false,"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-997X","authenticated-orcid":false,"given":"Chiara","family":"De Philippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierina","family":"Navarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mancosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Taurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pierluigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"2427_CR1","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295\u2013312.","journal-title":"Am J Hematol"},{"key":"2427_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.radonc.2022.08.007","volume":"175","author":"HS Ababneh","year":"2022","unstructured":"Ababneh HS, Abramson JS, Johnson PC, Patel CG. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. Radiother Oncol. 2022;175:65\u201372.","journal-title":"Radiother Oncol"},{"key":"2427_CR3","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38:3119\u201328.","journal-title":"J Clin Oncol"},{"key":"2427_CR4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19:342\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"2427_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","volume":"105","author":"AJ Sim","year":"2019","unstructured":"Sim AJ, Jain MD, Figura NB, Shah BD, Khimani F, Lazaryan A, et al. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019;105:1012\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2427_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"2427_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl J Med. 2019;380:45\u201356.","journal-title":"N. Engl J Med"},{"key":"2427_CR8","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140:349\u201358.","journal-title":"Blood"},{"key":"2427_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","volume":"30","author":"N Frey","year":"2017","unstructured":"Frey N. Cytokine release syndrome: Who is at risk and how to treat. Best Pr Res Clin Haematol. 2017;30:336\u201340.","journal-title":"Best Pr Res Clin Haematol"},{"key":"2427_CR10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ijrobp.2005.09.030","volume":"64","author":"C Martens","year":"2006","unstructured":"Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, et al. Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin\u2019s lymphoma. Int J Radiat Oncol Biol Phys. 2006;64:1183\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2427_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","volume":"91","author":"YD Tseng","year":"2015","unstructured":"Tseng YD, Chen YH, Catalano PJ, Ng A. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015;91:223\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2427_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.prro.2019.09.013","volume":"10","author":"A Kim","year":"2020","unstructured":"Kim A, Stevenson P, Cassaday RD, Soma L, Fromm JR, Gopal AK, et al. Impact of double- or triple-hit pathology on rates and durability of radiation therapy response among patients with relapsed or refractory large B-cell lymphoma. Pr Radiat Oncol. 2020;10:44\u201352.","journal-title":"Pr Radiat Oncol"},{"key":"2427_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/0360-3016(95)00214-8","volume":"33","author":"WC Dewey","year":"1995","unstructured":"Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 1995;33:781\u201396.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2427_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104.","journal-title":"J Hematol Oncol"},{"key":"2427_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"2427_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2427_CR17","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145\u201354.","journal-title":"Nat Med"},{"key":"2427_CR18","unstructured":"Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, et al. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium. Blood Adv. 2023:bloodadvances.2023011489."},{"key":"2427_CR19","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020;4:2871\u201383.","journal-title":"Blood Adv"},{"key":"2427_CR20","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl J Med. 2017;377:2531\u201344.","journal-title":"N. Engl J Med"},{"key":"2427_CR21","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017;7:1404\u201319.","journal-title":"Cancer Discov"},{"key":"2427_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.tiv.2015.05.016","volume":"30","author":"L Schultz","year":"2015","unstructured":"Schultz L, Zurich MG, Culot M, da Costa A, Landry C, Bellwon P, et al. Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models. Toxicol Vitr. 2015;30:138\u201365.","journal-title":"Toxicol Vitr"},{"key":"2427_CR23","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S0140-6736(09)61299-X","volume":"374","author":"C Soussain","year":"2009","unstructured":"Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374:1639\u201351.","journal-title":"Lancet"},{"key":"2427_CR24","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4:5607\u201315.","journal-title":"Blood Adv"},{"key":"2427_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/hon.118_2630","volume":"37","author":"V Bachanova","year":"2019","unstructured":"Bachanova V, Westin J, Tam C, Borchmann P, Jaeger U, McGuirk J, et al. Correlative analyses of cytokine release syndrome and neurological events in tisagenlecleucel\u2010treated relapsed\/refractory diffuse large B\u2010cell lymphoma patients. Hematol Oncol. 2019;37:308\u201310.","journal-title":"Hematol Oncol"},{"key":"2427_CR26","doi-asserted-by":"publisher","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.12.021","volume":"29","author":"H Hubbeling","year":"2023","unstructured":"Hubbeling H, Silverman EA, Michaud L, Tomas AA, Shouval R, Flynn J, et al. Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy. Transpl Cell Ther. 2023;29:259.e1\u2013259.e10.","journal-title":"Transpl Cell Ther"},{"key":"2427_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.clml.2021.07.002","volume":"21","author":"S Ghafouri","year":"2021","unstructured":"Ghafouri S, Fenerty K, Schiller G, de Vos S, Eradat H, Timmerman J, et al. Real-world experience of axicabtagene ciloleucel and tisagenlecleucel for relapsed or refractory aggressive B-cell Lymphomas: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2021;21:861\u201372.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02427-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02427-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02427-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T07:03:23Z","timestamp":1736492603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02427-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2427"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02427-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3573162\/v1","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors decalre no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}